Amersham’s Metastron (Strontium-89)
Executive Summary
Injectable cancer pain drug is being launched June 28 at a list price of $1,850 for a 4 mCi single-dose vial. One dose, delivered in an outpatient procedure, "usually is effective for an average of six months." Metastron, approved by FDA on June 18, ("The Pink Sheet" June 21, T&G-1) will be promoted to urology and medical oncology specialists by Zeneca and to nuclear medicine, radiopharmacy, and radiation oncology experts by Amersham, under a worldwide co-promotion agreement.